Zila, Inc. to Release Fiscal 2007 First Quarter Results and Hold Teleconference Regarding Transition to Cancer Detection Company
November 30 2006 - 8:30AM
Business Wire
Zila, Inc. (Nasdaq: ZILA) will release financial results for the
fiscal 2007 first quarter ended October 31, 2006, at the market
close on Thursday, December 7, 2006. The Company will also hold a
teleconference to review the Company's financial results and the
completion of its transition to a cancer detection company through
its recent financing and acquisition of Professional Dental
Technologies, Inc. (�Pro-Dentec��). Any investor or interested
individual can listen to the teleconference, which is scheduled to
begin at 1:30 p.m. PST (4:30 p.m. EST) on December 7, 2006. To
participate in the teleconference, please call toll-free
877-407-8031 (or 201-689-8031 for international callers)
approximately 10 minutes prior to the above start time. You may
also listen to the teleconference live via the Internet at
www.zila.com. For those unable to attend, the website will host an
archive of the call. A telephone playback will be available for 48
hours beginning at 9:30 p.m. PST on December 7, 2006. The playback
can be accessed by calling 877-660-6853 (or 201-612-7415 for
international callers) and providing passcode 286 and Conference ID
222192. About Zila, Inc. Zila, Inc., headquartered in Phoenix, is a
leading cancer diagnostic company initially focused on oral cancer:
Zila Pharmaceuticals is dedicated to establishing ViziLite(R) Plus
as the new standard of care for the early detection of oral
abnormalities that could lead to cancer, with initial focus on the
dental market through Pro-Dentec(R), a leading designer,
manufacturer and marketer of products exclusively to dental
professionals for Soft Tissue Management (STM(R)) including the
Rota-dent(R) Professional Powered Brush, the Pro-Select3(R)
Piezo-Ultrasonic Scaler System and a suite of pharmaceutical STM(R)
products for both in-office and home-care use. Zila Biotechnology
is focused on achieving regulatory approval for the next generation
oral cancer diagnostic, OraTest(R), followed by the development of
additional applications of its cancer detection technologies. For
more information about Zila, visit www.zila.com. This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These forward-looking statements are based
largely on Zila's expectations or forecasts of future events, can
be affected by inaccurate assumptions and are subject to various
business risks and known and unknown uncertainties, a number of
which are beyond the Company's control. Therefore, actual results
could differ materially from the forward-looking statements
contained herein. A wide variety of factors could cause or
contribute to such differences and could adversely impact revenues,
profitability, cash flows and capital needs. There can be no
assurance that the forward-looking statements contained in this
press release will, in fact, transpire or prove to be accurate. For
a more detailed description of these and other cautionary factors
that may affect Zila's future results, please refer to Zila's Form
10-K for its fiscal year ended July 31, 2006. Zila, Inc. (Nasdaq:
ZILA) will release financial results for the fiscal 2007 first
quarter ended October 31, 2006, at the market close on Thursday,
December 7, 2006. The Company will also hold a teleconference to
review the Company's financial results and the completion of its
transition to a cancer detection company through its recent
financing and acquisition of Professional Dental Technologies, Inc.
("Pro-Dentec(R)"). Any investor or interested individual can listen
to the teleconference, which is scheduled to begin at 1:30 p.m. PST
(4:30 p.m. EST) on December 7, 2006. To participate in the
teleconference, please call toll-free 877-407-8031 (or 201-689-8031
for international callers) approximately 10 minutes prior to the
above start time. You may also listen to the teleconference live
via the Internet at www.zila.com. For those unable to attend, the
website will host an archive of the call. A telephone playback will
be available for 48 hours beginning at 9:30 p.m. PST on December 7,
2006. The playback can be accessed by calling 877-660-6853 (or
201-612-7415 for international callers) and providing passcode 286
and Conference ID 222192. About Zila, Inc. Zila, Inc.,
headquartered in Phoenix, is a leading cancer diagnostic company
initially focused on oral cancer: -- Zila Pharmaceuticals is
dedicated to establishing ViziLite(R) Plus as the new standard of
care for the early detection of oral abnormalities that could lead
to cancer, with initial focus on the dental market through
Pro-Dentec(R), a leading designer, manufacturer and marketer of
products exclusively to dental professionals for Soft Tissue
Management (STM(R)) including the Rota-dent(R) Professional Powered
Brush, the Pro-Select3(R) Piezo-Ultrasonic Scaler System and a
suite of pharmaceutical STM(R) products for both in-office and
home-care use. -- Zila Biotechnology is focused on achieving
regulatory approval for the next generation oral cancer diagnostic,
OraTest(R), followed by the development of additional applications
of its cancer detection technologies. For more information about
Zila, visit www.zila.com. This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These forward-looking statements are based largely on
Zila's expectations or forecasts of future events, can be affected
by inaccurate assumptions and are subject to various business risks
and known and unknown uncertainties, a number of which are beyond
the Company's control. Therefore, actual results could differ
materially from the forward-looking statements contained herein. A
wide variety of factors could cause or contribute to such
differences and could adversely impact revenues, profitability,
cash flows and capital needs. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate. For a more detailed
description of these and other cautionary factors that may affect
Zila's future results, please refer to Zila's Form 10-K for its
fiscal year ended July 31, 2006.
Zila (NASDAQ:ZILA)
Historical Stock Chart
From May 2024 to Jun 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2023 to Jun 2024